Enzolytics, Inc. is a drug development company. The Company is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	132K 114K 107K 97.78K 183K 12.48M 183K 1.26M 491K 6.4M 496K 486K 20.63M	P/E 2009 *	-	P/E 2010	-0.29x
Enterprise Value	460K 396K 372K 340K 636K 43.42M 638K 4.4M 1.71M 22.28M 1.73M 1.69M 71.77M	EV / Sales 2009	325,315,067x	EV / Sales 2010	210,445,953x
Free-Float	100%	Yield 2009 *	-	Yield 2010	-

31/07/24	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
29/07/24	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI
02/05/24	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
25/03/24	Enzolytics, Inc. Announces Board Changes	CI
25/03/24	Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	CI
25/03/24	Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	CI
26/06/23	Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	CI
21/04/23	Enzolytics, Inc. Provides Update on Clinical Trials	CI
16/04/23	Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	CI
08/02/23	Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	CI
03/01/23	Enzolytics to Develop Feline Monoclonal Antibodies	CI
13/12/22	Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	CI
16/11/22	Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	CI

05/08/24	Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside...	AQ
28/03/24	Stocks Under 5¢ Watch Now! CLNV, HNRC, HALB, ENZC, RSHN	AQ
12/03/24	RushNet (OTC: RSHN) and Royal Caridea Join Forces to Transform Aquaculture Harvesting Shrimp and more...SPZI, HALB, ENZC, HNRC	AQ
01/03/24	Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI	AQ
07/02/24	OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO	AQ

Manager	Title	Age	Since
Steven Sharabura CEO	Chief Executive Officer	-	20/03/2024
Diana Zhabilov DFI	Director of Finance/CFO	-	20/03/2024
Harry Zhabilov CEO	Chief Executive Officer	59	15/06/2017

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	18/03/2024
Lachezar Ivanov BRD	Director/Board Member	-	18/03/2024

Enzolytics Inc Share Price Other OTC

Stocks

Biotechnology & Medical Research

Valuation : Enzolytics Inc

Latest news : Enzolytics Inc

Press Releases : Enzolytics Inc

Managers and Directors : Enzolytics Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZOLYTICS INC	-.--%	+81.16%	-	-	2.42M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+99.78%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+85.24%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+377.83%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-13.58%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	+0.49%	+1.19%	+26.78%	+18.09%	25.74B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-16.76%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+375.70%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.12%	-1.45%	-6.93%	+549.01%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+165.57%	14.62B
Average	-0.73%	+0.26%	+41.96%	+182.32%	31.01B
Weighted average by Cap.	-1.11%	+0.18%	+37.77%	+141.78%

	2009	2010
Net sales	0.01 0.01 0.01 0.01 0.02 1.39 0.02 0.14 0.05 0.71 0.06 0.05 2.3	0.04 0.03 0.03 0.03 0.05 3.49 0.05 0.35 0.14 1.79 0.14 0.14 5.77
Net income	-970K -835K -785K -717K -1.34M -91.56M -1.35M -9.28M -3.6M -46.98M -3.64M -3.56M -151M	-7.51M -6.47M -6.08M -5.56M -10.4M -709M -10.42M -71.89M -27.89M -364M -28.22M -27.6M -1.17B
Net Debt	924K 795K 748K 683K 1.28M 87.22M 1.28M 8.84M 3.43M 44.75M 3.47M 3.39M 144M	328K 282K 265K 242K 453K 30.94M 455K 3.13M 1.22M 15.87M 1.23M 1.2M 51.14M